ChromaDex Corporation (CDXC)
NASDAQ: CDXC
· Real-Time Price · USD
7.87
-0.07 (-0.88%)
At close: Mar 18, 2025, 3:59 PM
-0.88% (1D)
| Bid | 7.88 |
| Market Cap | 611.9M |
| Revenue (ttm) | 98.01M |
| Net Income (ttm) | 8.55M |
| EPS (ttm) | 0.11 |
| PE Ratio (ttm) | 71.54545454545455 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 7.89 |
| Volume | 541,672 |
| Avg. Volume (20D) | 809,373 |
| Open | 7.91 |
| Previous Close | 7.94 |
| Day's Range | 7.75 - 7.92 |
| 52-Week Range | 2.31 - 9.18 |
| Beta | 2.21 |
About CDXC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CDXC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CDXC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
ChromaDex Corporation is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
ChromaDex shares are trading higher after the comp...
Unlock content with
Pro Subscription
6 months ago
ChromaDex shares are trading higher after Roth MKM maintained a Buy rating on the stock and raised its price target from $6 to $8.
2 months ago · seekingalpha.com
ChromaDex Capitalizes On Longevity Boom But Valuation Remains HighChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial pe...
2 months ago · businesswire.com
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 ResultsLOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 mil...
